| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director | Director, Former 10% Owner
6 companies
Amir Nashat is Director at RNAC and has filed Form 4s across 6 companies. Amir Nashat's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $19.8M at current prices.
Historically, Amir Nashat's trades have earned a below-average insider score of 49/100 across 3 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +16.9%.
The biggest single holding is RNAC (~$17.2M) as Director. Net of sales, the RNAC filings show accumulation of 1,020,042 shares.
Amir Nashat has 58 Form 4 filings on record from May 2015 to June 2026, across 6 companies: Director, 10% Owner at Camp4 Therapeutics (CAMP), 2024–2026; Director at Scholar Rock (SRRK), 2018–2024; Director at Syros Pharmaceuticals (SYRS), 2016–2022, and 3 more.
The 218 reported transactions were 104 open-market sales, 36 other transactions, 30 conversions and 28 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 7 purchases worth about $28.7M and 17 sales worth about $28.7M.
The largest open-market purchase was 909,090 shares of CAMP at an average $11.00 on October 15, 2024, about $10.0M. Twelve months later CAMP was down 68%.
The largest open-market sale was 425,000 shares of FATE at an average $16.78 on December 12, 2018, about $7.1M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | CAMP Camp4 Therapeutics Corp | Director, 10% Owner | Buy | 1,307,189 | $1.53 | $1,999,999.17 | -117.8% | +105.8% | +52.9% | |
| Oct 15, 2024 | CAMP Camp4 Therapeutics Corp | Director, 10% Owner | Buy | 909,090 | $11.00 | $9,999,990.00 | New | -63.3% | -68.0% | |
| Jun 22, 2022 | SRRK Scholar Rock Holding Corp | Director | Buy | 1,197,992 | $4.90 | $5,870,160.80 | -120.9% | +62.1% | +65.9% | |
| Aug 1, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 62,005 | $22.53 | $1,397,066.29 | -84.9% | - | - | |
| Jul 30, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 118,333 | $22.51 | $2,663,114.73 | -91.0% | - | - | |
| Jul 24, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 81,899 | $22.51 | $1,843,150.96 | -86.5% | - | - | |
| Jul 22, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 71,166 | $22.52 | $1,602,505.66 | -84.0% | - | - | |
| Jan 30, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 53,017 | $14.16 | $750,959.30 | -3.5% | - | - | |
| Jan 29, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 97,203 | $14.16 | $1,376,589.07 | -6.0% | - | - | |
| Jan 28, 2019 | FATE Fate Therapeutics Inc | Director | Sell | 70,000 | $13.78 | $964,768.00 | -4.1% | - | - |